[ Inside the business ]

GILD stock analysis

GILD · Gilead Sciences, Inc.

Biological products, (no diagnostic substances). Growing 7%. Loses 8¢ on every dollar.

Watch: growth that has stopped speeding up.

The future, in 7 questions

Priced in: 2.7× sales in 5 yrs. Evidence: sales +7% · loss growing · In-body cell therapy rising.

01 What's priced in?2.7× sales in 5 yrs
Sales now$31.0B
Needed in 5 yrs$83.3B
02 Is the wave rising?In-body cell therapy · 2.8×
'20'21'22'23'24'2514
#15 of 20 mentioning it
03 Will customers keep buying?Cardinal Health: 29% of sales
Cardinal Health 29%Mckesson 24%Cencora 21%Everyone else
Prepaid $57MSales +7%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Loss growing: −8¢ per $1
'21'22'23'24'25−8¢
Before running costs: 79% → 79%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −0.1%/yrDebt $26.2B
07 What could break it?1 to watch
  • Growth peaked

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth peaked.

Sales growth +4%, +10%, then +7% vs. a year ago.

What could go wrong

Steadier than most.

It has moved 0.3× the market. In the 2018 q4 selloff it fell 18% while the market fell 14%. Debt is moderate.

Speculative check

Not classified.

Not Self-funding because of: operating loss, net loss, debt over 4× operating profit.

What they sell

49% HIV Products, Biktarvy.

HIV Products, Biktarvy 49% · HIV Products, Descovy 12% · Liver Disease 11% · Trodelvy 6% · other

Where each dollar goes

8¢ loss.

20¢ to make what it sells, 88¢ on research and overhead, nothing left over. Revenue $31.0B in the last 12 months.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators.

Competitive advantage

8 of 10 years.

Returns beat its 7.1% cost of capital in 8 of the last 10 years. Gross margin went from 86% to 79%.

Future bets

20% on research.

$6.3B a year on R&D. $699M on equipment and buildings.

All figures from Gilead Sciences, Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.